The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...